Analysis Transgene SA (0OCQ)
5/30/2024
Analysis of Transgene SA (0OCQ)
Transgene SA is a biotechnology company that focuses on the development of immunotherapies for the treatment of cancer. Looking at the recent data, we can see that the stock price has been fluctuating within a range. The Relative Strength Index (RSI) is around 44, indicating a neutral position. The Moving Average Convergence Divergence (MACD) is slightly negative, suggesting a potential bearish trend.The stock has been trading below the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA), indicating a bearish sentiment in the short term.
Overall, based on the technical indicators, Transgene SA may experience some downward pressure in the near future. Investors should closely monitor the stock for any potential trend reversal or significant developments in the company's pipeline that could impact its stock price.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The company's financials show a strong cash flow, with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet indicates a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31%, with a return on assets of 22.07% and return on equity of 147.25%. The fiscal year ends on September 30, 2023, with a most recent quarter ending on March 31, 2024.In terms of income statement, the company has an EBITDA of $131.39 billion, revenue of $381.62 billion, and a net income to common of $100.39 billion. The diluted EPS is $6.43, gross profit is $169.14 billion, and revenue per share is $24.54. The company experienced a negative quarterly revenue growth of -4.3% and a negative quarterly earnings growth year over year of -2.2%.
The stock statistics show a short ratio of 1.53, with 99.29 million shares shorted out of 15.31 billion float shares. The stock has an average 10-day volume of 46.86 million and an average 90-day volume of 57.50 million. The stock price summary includes a beta of 1.264, with a 50-day moving average of $176.26 and a 200-day moving average of $181.04. The 52-week low and high prices are $164.08 and $199.62, respectively.
In terms of valuations metrics, the company has a PEG ratio of 26.32, forward PE of 26.32, and trailing PE of 29.59. The enterprise value is $2.95 trillion, with a price to book ratio of 39.34, price to sales ratio of 7.65, enterprise to EBITDA ratio of 22.76, and enterprise to revenue ratio of 7.73. The market capitalization is $2.92 trillion.
Lastly, the company's dividends and splits information show a payout ratio of 14.93%, with a forward annual dividend rate of $1 and a trailing annual dividend rate of $0.97. The company's dividend dates include an ex-dividend date of May 10, 2024, a dividend date of May 16, 2024, and a last split date of August 31, 2020, with a 4-for-1 split factor. The 5-year average dividend yield is 0.73%, with a forward annual dividend yield of 0.53% and a trailing annual dividend yield of 0.51%.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.5%
- The next quarter growth rate is 4.8%
- The current quarter growth rate is 5.6%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 11%
- The past 5 years compound annual growth rate (CAGR) is 20.15%
It can be observed that the company is expected to experience a significant increase in growth rate compared to the past 5 years, with a particularly high growth rate projected for the next 5 years. This indicates positive expectations and potential for expansion and development in the future.
Price target
The analysts' forecast for the future price of the security paper is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security paper, with the low end at $164, the high end at $250, and the average forecast at $202.26. The current price is below both the average and median forecast, indicating that there is potential for growth according to the analysts' predictions.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been relatively stable, with gross profit ranging from around $105 billion to $169 billion.
3. Operating income has also shown a consistent growth trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has been increasing over the years, from $57.4 billion in 2020 to $97 billion in 2023.
5. Earnings per share (EPS) have shown a slight fluctuation but have generally increased from $3.28 in 2020 to $6.16 in 2023.
6. The company has been able to maintain a healthy EBITDA margin, with EBITDA reaching $129.2 billion in 2023.
7. Despite an increase in income tax expenses, the company has managed to grow its net income continuously.
8. The company has been able to effectively manage its operating expenses, with a slight increase in research and development costs over the years.
9. Non-operating interest expenses have been relatively stable, indicating a consistent financial management approach.
10. The number of basic and diluted shares outstanding has remained stable over the years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
6. The company has been relying more on non-current assets to support its operations.
7. There has been a consistent increase in shareholders' equity, indicating a positive trend in the company's financial health.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. Financing activities have a significant impact on the company's cash position, with large amounts being used for common stock repurchase and debt issuance.
4. Investing activities show a mix of acquisitions, investments, and capital expenditures, with varying levels of cash flow impact each year.
5. Interest paid and income tax paid figures provide insights into the company's financial obligations and tax management strategies.
6. The end cash position has been fluctuating, but overall the company has maintained a healthy cash reserve over the years.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next two years. The average estimates are showing an increase compared to the year-ago EPS figures, indicating potential growth in earnings for the company.
MACD of 0OCQ
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
